We are developing NRL-2, a proprietary nasal spray formulation of a benzodiazepine (other than diazepam) and Intravail®, for the treatment of acute panic attacks in patients with panic disorders (PD), general anxiety disorders (GAD) and other related anxiety disorders.* There are multiple oral therapies approved by the FDA for depression and GADs, but there are currently no medications approved by the FDA for the treatment of acute panic attacks. We believe that NRL-2, if approved, could provide the patients suffering from acute panic attacks with a rapid onset treatment option for acute panic attacks. We expect to submit an IND and begin clinical trials in 2022.
*NRL-2 is an investigational drug candidate being developed for children and adults who require intermittent use of benzodiazepines for acute anxiety episodes and has not been approved by FDA for any indication.